These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16516098)

  • 1. Levosimendan improves cardiopulmonary resuscitation and survival by K(ATP) channel activation.
    Cammarata GA; Weil MH; Sun S; Huang L; Fang X; Tang W
    J Am Coll Cardiol; 2006 Mar; 47(5):1083-5. PubMed ID: 16516098
    [No Abstract]   [Full Text] [Related]  

  • 2. Levosimendan improves postresuscitation outcomes in a rat model of CPR.
    Huang L; Weil MH; Sun S; Cammarata G; Cao L; Tang W
    J Lab Clin Med; 2005 Nov; 146(5):256-61. PubMed ID: 16242524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan improves the initial outcome of cardiopulmonary resuscitation in a swine model of cardiac arrest.
    Koudouna E; Xanthos T; Bassiakou E; Goulas S; Lelovas P; Papadimitriou D; Tsirikos N; Papadimitriou L
    Acta Anaesthesiol Scand; 2007 Sep; 51(8):1123-9. PubMed ID: 17697310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Levosimendan in cardiopulmonary resuscitation.
    Varvarousi G; Stefaniotou A; Varvaroussis D; Aroni F; Xanthos T
    Eur J Pharmacol; 2014 Oct; 740():596-602. PubMed ID: 24972240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism by which activation of delta-opioid receptor reduces the severity of postresuscitation myocardial dysfunction.
    Fang X; Tang W; Sun S; Huang L; Huang Z; Weil MH
    Crit Care Med; 2006 Oct; 34(10):2607-12. PubMed ID: 16775573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resuscitation from adrenaline resistant electro-mechanical dissociation facilitated by levosimendan in a young man with idiopathic dilated cardiomyopathy.
    Tsagalou EP; Nanas JN
    Resuscitation; 2006 Jan; 68(1):147-9. PubMed ID: 16325323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection?
    Hearse DJ
    Cardiovasc Res; 1995 Jul; 30(1):1-17. PubMed ID: 7553711
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty.
    Samimi-Fard S; García-González MJ; Domínguez-Rodríguez A; Abreu-González P
    Int J Cardiol; 2008 Jul; 127(2):284-7. PubMed ID: 17643519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is levosimendan an inoprotective drug in patients with acute coronary syndrome undergoing surgical revascularization?].
    Lehmann A; Boldt J; Lang J; Isgro F; Blome M
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2003 Sep; 38(9):577-82. PubMed ID: 12975736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan in heart failure after surgical repair of cardiac rupture.
    Torrado H; Ventura JL; Ruiz-Majoral A; Farrero E; Rodriguez-Castro D; Carrio ML; Miralles A
    Minerva Cardioangiol; 2009 Feb; 57(1):137-8. PubMed ID: 19202525
    [No Abstract]   [Full Text] [Related]  

  • 13. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases.
    García-González MJ; Domínguez-Rodríguez A; Ferrer-Hita JJ
    J Clin Pharmacol; 2005 Jun; 45(6):704-8. PubMed ID: 15901754
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful use of levosimendan in a patient during cardiopulmonary bypass.
    Iriz E; Erer D; Unal Y; Zor H; Ozkose Z; Ozdogan ME
    J Card Surg; 2007; 22(2):153-6. PubMed ID: 17338755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotection: a new paradigm in the management of acute heart failure syndromes.
    Maytin M; Colucci WS
    Am J Cardiol; 2005 Sep; 96(6A):26G-31G. PubMed ID: 16181820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based use of levosimendan in different clinical settings.
    De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade M
    Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The case for levosimendan.
    De Keulenaer BL
    Crit Care Resusc; 2008 Sep; 10(3):180. PubMed ID: 18798714
    [No Abstract]   [Full Text] [Related]  

  • 18. Levosimendan in cardiogenic shock: the magic drug for every patient?
    Smetana P; Geppert A
    Crit Care Med; 2007 Dec; 35(12):2862-4. PubMed ID: 18043208
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass.
    Stocker CF; Shekerdemian LS; Nørgaard MA; Brizard CP; Mynard JP; Horton SB; Penny DJ
    Crit Care Med; 2007 Jan; 35(1):252-9. PubMed ID: 17133188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs.
    Papp JG; Pollesello P; Varró AF; Végh AS
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):129-35. PubMed ID: 16891290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.